RNA
Is mRNA a Gene Therapy? Unpacking the Evolving Regulatory Debate
Cynthia A. Challener, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
PAO-03-25-NI-06Mar 26, 2025
RNA
What new opportunities are emerging for mRNA technology, and how is the portfolio of applications expanding beyond vaccines?
Pharma's Almanac
PAO-03-25-RT-02Mar 26, 2025
RNA
Beyond mRNA Vaccines: The Expanding World of RNA-Based Therapeutics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-24Mar 21, 2025
New Integrated mRNA Offering
Building on Experience and Investing in an Integrated mRNA Offering
Jessica Madigan; Normand Blais
BIOVECTRA
PAO-07-23-CL-03Jul 31, 2023
Custom Lipid Nanoparticle Development
The Value of a Custom Lipid Solutions Provider for mRNA Delivery
Lauren Longobardi, Ph.D.; Rima Jaber, Ph.D.; Sebastian Detlefsen, Dr.-Ing.
Evonik
PAO-11-022-CL-17Jan 05, 2023
mRNA Manufacturing
Investing in the Future of mRNA Manufacturing
Esther Yoo, Ph.D.
Samsung Biologics
PAO-11-022-CL-02Nov 16, 2022
mRNA Manufacturing
Overcoming Bottlenecks in mRNA Manufacturing
Pierre Catignol; Huisub Lim
Samsung Biologics
PAO-10-022-CL-04Oct 24, 2022
mRNA
Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-022-NI-02Oct 11, 2022
RNA
Closing the Developability Gap for RNA Therapeutics and Vaccines with a Fit-for-Purpose Analysis Kit
Susan Darling; Quincy Mehta
SCIEX
PAO-07-022-CL-06Jul 19, 2022
Vaccine and Cell & Gene Therapies
Expanding Manufacturing Capacity to Meet Market Demand for Vaccines and Cell and Gene Therapeutics
lrike Fiedler Dr. Rer. Nat.
IDT Biologika
PAO-04-022-CL-02Apr 13, 2022
Column: Technology
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-03-022-NI-02Mar 23, 2022
mRNA
Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects
Scott Doncaster; Marc Sauer, Ph.D.
BIOVECTRA
PAO-02-022-CL-07Mar 12, 2022
Strategic Partnership
eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to Access mRNA Technologies
eTheRNA Immunotherapies NV
PR-M02-22-02Feb 03, 2022
mRNA Vaccine Manufacturing
Presenting an Integrated Solution for mRNA Vaccine Manufacturing
Mark Bamforth; Dave Stevens
Arranta Bio
PAO-01-22-R250-04Jan 26, 2022
mRNA Manufacturing
Serving an Accelerated Market with mRNA Production
Mark Bamforth
Arranta Bio
PAO-11-21-CL-06Dec 08, 2021
Investing in mRNA Production
Michael Wourms
Arranta Bio
PA766Nov 22, 2021
mRNA Manufacturing
Limiting Risk In mRNA Development and Production
Doug Kennedy
Arranta Bio
PAO-11-21-CL-05Nov 22, 2021
mRNA Manufacturing
Integrating a Fragmented mRNA Supply Chain
Dave Stevens
Arranta Bio
PAO-11-21-CL-04Nov 22, 2021
mRNA Vaccines
BIOVECTRA mRNA Vaccine and Biomanufacturing Facility Announced
BIOVECTRA
PR-M11-21-02Nov 18, 2021
mRNA
Integrated Support Facilitates mRNA Product Development and Commercialization
Michael Wourms; Dave Stevens
Arranta Bio
PAO-10-21-CL-15Oct 26, 2021